Clinical pharmacology of emicizumab for the treatment of hemophilia A.

Koichiro Yoneyama,Christophe Schmitt,Agnès Portron,Anna Kiialainen,Naoki Kotani,Felix Jaminion,Sylvie Retout,Joanne I Adamkewicz

Expert review of clinical pharmacology（2023）

引用 0|浏览5

暂无评分

摘要

The translation of emicizumab PK/PD into clinical effects was demonstrated in several phase III studies, which showed remarkable bleed control and a favorable safety profile in PwHA. These emicizumab attributes, together with the convenience of use (infrequent SC injections), offer a novel paradigm for the management of PwHA.

查看译文

关键词

Bispecific antibody, bleeding prophylaxis, clinical pharmacology, emicizumab, factor VIII activity, hemophilia A, pharmacodynamics, pharmacokinetics

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要